- Home
- IMNN vs TLPH Comparison
IMNN vs TLPH Comparison
Compare IMNN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNN | TLPH |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 64.7M |
| IPO Year | 1985 | 2011 |
Fundamental Metrics
Financial Performance| Metric | IMNN | TLPH |
|---|---|---|
| Price | $3.16 | $1.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $182.61 | $6.00 |
| AVG Volume (30 Days) | 38.6K | ★ 428.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.14 | $0.38 |
| 52 Week High | $41.22 | $1.57 |
Technical Indicators
Market Signals| Indicator | IMNN | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 44.11 |
| Support Level | $3.80 | $1.02 |
| Resistance Level | $4.00 | $1.22 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 1.65 | 36.67 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.